Company / Accounts Receivable
OptimizeRx Corp Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$38.2M
FY2025
5-year range
$17.9M / $38.2M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $36M to $38M over the past 2 years.
Based on SEC 10-K filings.
$38M in FY2025 with a 5-year CAGR of +16.4%.
Improved from $36M to $38M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +19.9%
- 5-Year CAGR
- +16.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +16.4%, indicating consistent growth.
- In FY2025, accounts receivable increased 0.0% year-over-year.
- Lowest accounts receivable in the period was in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $38.2M | +0.0% |
| FY2024 | $38.2M | +5.4% |
| FY2023 | $36.3M | +63.6% |
| FY2022 | $22.2M | +23.9% |
| FY2021 | $17.9M | +0.0% |
| FY2020 | $17.9M | +141.1% |
| FY2019 | $7.4M | +14.9% |
| FY2018 | $6.5M | +186.1% |
| FY2017 | $2.3M | -26.2% |
| FY2016 | $3.1M | +7.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026